← Back to home

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV)

Clinical trials for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV) explained in plain language.

Never miss a new study

Get alerted when new ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV) trials appear

Sign up with your email to follow new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

First look: new drug tested for rare autoimmune disease

Disease control Completed

This was a very small, early-stage study to gather initial information on a potential new drug called MT-2990 for ANCA-associated vasculitis (AAV), a rare autoimmune disease. It involved only 5 patients with active AAV. The main goal was to explore the drug's safety, how it works…

Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV)

Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV)

Get alerted when new ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV) trials appear

First look: new drug tested for rare autoimmune disease